Document Detail


CD44 variant overexpression in gallbladder carcinoma associated with tumor dedifferentiation.
MedLine Citation:
PMID:  11180088     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Recent studies have suggested a correlation between increased or decreased expression of CD44 variant molecules and tumor metastasis. CD44 expression in gallbladder carcinoma was examined and compared with tumor differentiation. METHODS: Eighty-three samples of gallbladder carcinoma, 17 gallbladder adenoma samples, and 66 normal control mucosa samples were stained immunohistochemically for CD44 standard form (CD44s), variant 3 (CD44v3), and variant 6 (CD44v6). RNA extracted from nine patients with carcinoma also was investigated with reverse transcriptase-polymerase chain reaction (RT-PCR) analysis and Southern blot hybridization (SBH) for the CD44 gene. RESULTS: Normal gallbladder mucosa showed strong, membranous staining for CD44s but not for CD44v3 or CD44v6. In gallbladder tumors, CD44s was stained as strongly as it was in normal mucosa, but immunoreactivity for CD44v3 and CD44v6 also was significant. In well differentiated, advanced adenocarcinomas (n = 38), CD44s immunoreactivity was significantly lower in the invasive component than in the intramucosal component of the tumors (P = 0.0048). Immunoreactivity for CD44v3 and CD44v6 in moderately and poorly differentiated areas was significantly higher than in well differentiated areas (P < 0.0001 and P = 0.0378, respectively). RT-PCR and SBH signals for CD44v3 and CD44v6, including exons 7 and 10, were strong in carcinoma samples but weak in normal samples, in line with the results of immunohistochemistry. The prognosis of patients with gallbladder carcinoma was not associated significantly with altered expression of CD44s, CD44v3, or CD44v6. CONCLUSIONS: The current study demonstrated that CD44 variant overexpression in patients with gallbladder carcinoma was linked closely with histologic dedifferentiation rather than clinicopathologic factors, including prognosis.
Authors:
N Yanagisawa; T Mikami; H Mitomi; M Saegusa; M Koike; I Okayasu
Related Documents :
9846498 - High frequency expressions of cd44 standard and variant forms in non-small cell lung ca...
9139888 - Expression of beta 1,6 branched asparagine-linked oligosaccharides in non-mitotic and n...
18372518 - Cd44 expression in metastatic and non-metastatic non-small cell lung cancers.
9108888 - Tgf beta in prostate cancer: a growth inhibitor that can enhance tumorigenicity.
11932908 - Frequent impairment of the spindle assembly checkpoint in hepatocellular carcinoma.
3625818 - Research strategy in industrial toxicology.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer     Volume:  91     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2001 Jan 
Date Detail:
Created Date:  2001-02-22     Completed Date:  2001-03-01     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  408-16     Citation Subset:  AIM; IM    
Affiliation:
Department of Pathology, Kitasato University School of Medicine, Kanagawa, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / immunology*,  pathology
Adenoma / immunology*,  pathology
Adult
Aged
Aged, 80 and over
Antigens, CD44 / genetics,  metabolism*
Antigens, Neoplasm / genetics,  metabolism*
Female
Gallbladder Neoplasms / immunology*,  pathology
Humans
Immunohistochemistry
Male
Middle Aged
Neoplasm Staging
Oligonucleotide Array Sequence Analysis
Reverse Transcriptase Polymerase Chain Reaction
Chemical
Reg. No./Substance:
0/Antigens, CD44; 0/Antigens, Neoplasm

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The role of computed tomography in the T classification of laryngeal carcinoma.
Next Document:  A Phase II study of paclitaxel in patients with recurrent malignant glioma using different doses dep...